Clinical characteristics of interim-PET negative patients with a positive end PET from the prospective HD08-01 FIL study

Luigi Rigacci, Benedetta Puccini, Alessandro Broccoli, Manjola Dona, Manuel Gotti, Andrea Evangelista, Armando Santoro, Maurizio Bonfichi, Alessandro Re, Michele Spina, Barbara Botto, Alessandro Pulsoni, Chiara Pagani, Caterina Stelitano, Flavia Salvi, Luca Nassi, Lara Mannelli, Sofia Kovalchuk, Daniela Gioia, Pier Luigi Zinzani

Research output: Contribution to journalArticlepeer-review


FDG-positron emission tomography (PET) performed early during therapy in advanced Hodgkin lymphoma patients has been confirmed as being important for progression-free survival. A group of patients with a negative interim-PET (i-PET) showed a positive end induction PET (e-PET). The aim of this study was to evaluate the clinical characteristics of patients with a positive e-PET as a secondary end point of the HD0801 study. A total of 519 patients with advanced-stage de novo Hodgkin lymphoma received initial treatment and underwent an i-PET. Patients with negative results continued the standard treatment. i-PET negative patients were then evaluated for response with an e-PET and those patients found to have a positive one were also then given a salvage therapy. Among 409 i-PET negative, 16 interrupted the therapy, 393 patients were evaluated with an e-PET, and 39 were positive. Sixteen out of 39 underwent a diagnostic biopsy and 15 were confirmed as HD. Seventeen out of 39 e-PET were reviewed according to the Deauville Score and, in sixteen, it was confirmed positive (10 DS 5, 6 DS 4). With the exception of high LDH value at diagnosis (p = 0.01; HR 95% CI 1.18-4.89), no clinical characteristics were significantly different in comparison with e-PET negative patients. Positive e-PET after a negative i-PET has a worse outcome when compared with i-PET positive patients salvaged with therapy intensification. It was not possible to identify clinical characteristics associated with a positive e-PET.

Original languageEnglish
Pages (from-to)283-291
Number of pages9
JournalAnnals of Hematology
Issue number2
Publication statusPublished - Feb 2020


  • Adult
  • Antineoplastic Combined Chemotherapy Protocols/administration & dosage
  • Autografts
  • Bleomycin/administration & dosage
  • Dacarbazine/administration & dosage
  • Disease-Free Survival
  • Doxorubicin/administration & dosage
  • Female
  • Fluorodeoxyglucose F18/administration & dosage
  • Hodgkin Disease/diagnostic imaging
  • Humans
  • Male
  • Positron-Emission Tomography
  • Prospective Studies
  • Stem Cell Transplantation
  • Survival Rate
  • Vinblastine/administration & dosage


Dive into the research topics of 'Clinical characteristics of interim-PET negative patients with a positive end PET from the prospective HD08-01 FIL study'. Together they form a unique fingerprint.

Cite this